BOSTON, July 05, 2023 (GLOBE NEWSWIRE) — Dear TransCode Therapeutics Shareholders, I want to express the optimism that permeates the management, board, and staff of TransCode as we navigate the ever-evolving oncology field and venture into the clinic with our lead candidate to treat metastatic disease. This optimism is also…Read More
TransCode Therapeutics Inc TransCode Therapeutics CEO Letter to Shareholders
